10-Deacetyl-7-xylosyl paclitaxelCAS# 90332-63-1 |
2D Structure
- Docetaxel
Catalog No.:BCN5342
CAS No.:114977-28-5
- ABT-751 (E7010)
Catalog No.:BCC1085
CAS No.:141430-65-1
- Epothilone A
Catalog No.:BCC1091
CAS No.:152044-53-6
- Honokiol
Catalog No.:BCN1001
CAS No.:35354-74-6
- Altretamine
Catalog No.:BCC1216
CAS No.:645-05-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 90332-63-1 | SDF | Download SDF |
PubChem ID | 46783796 | Appearance | Powder |
Formula | C50H57NO17 | M.Wt | 944.0 |
Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
Synonyms | 10-Deacetyl-7-xylosyltaxol; 10-Deacetylpaclitaxel 7-Xyloside; 10-Deacetyltaxol 7-Xyloside | ||
Solubility | H2O : < 0.1 mg/mL (insoluble) | ||
SMILES | CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)OC8C(C(C(CO8)O)O)O)C)O | ||
Standard InChIKey | ORKLEZFXASNLFJ-ODBGVJAMSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. 10-Deacetyl-7-xylosyl paclitaxel has long been used in Chinese clinics to treat cancer, it may target mitochondrial permeability transition pore (mPTP). |
10-Deacetyl-7-xylosyl paclitaxel Dilution Calculator
10-Deacetyl-7-xylosyl paclitaxel Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.0593 mL | 5.2966 mL | 10.5932 mL | 21.1864 mL | 26.4831 mL |
5 mM | 0.2119 mL | 1.0593 mL | 2.1186 mL | 4.2373 mL | 5.2966 mL |
10 mM | 0.1059 mL | 0.5297 mL | 1.0593 mL | 2.1186 mL | 2.6483 mL |
50 mM | 0.0212 mL | 0.1059 mL | 0.2119 mL | 0.4237 mL | 0.5297 mL |
100 mM | 0.0106 mL | 0.053 mL | 0.1059 mL | 0.2119 mL | 0.2648 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility. IC50 value: Target: Microtubule inhibitor 10-Deacetyl-7-xylosyl paclitaxel induced mitotic cell cycle arrest and apoptosis as measured by flow cytometry, DNA laddering, and transmission electron microscopy. Pro-apoptotic Bax and Bad protein expression was up-regulated and anti-apoptotic Bcl-2 and Bcl-XL expression down-regulated, which lead to a disturbance of the mitochondrial membrane permeability and to the activation of caspase-9. In turn, caspase-9 activated downstream caspases-3 and -6, but not caspase-8. Bid was also activated by caspase-3. Reversely, treatment with a caspase-10-specific inhibitor could not protect PC-3 cells from 7-xylosyl-10-deacetyl-paclitaxel-triggered apoptosis. Moreover, 7-xylosyl-10-deacetylpaclitaxel had no effect on the expression of CD95 and NF-kappaB proteins, indicating that apoptosis was induced through the mitochondrial-dependent pathway in PC-3 cells.
References:
[1]. Jiang S, et al. Activation of the mitochondria-driven pathway of apoptosis in human PC-3 prostate cancer cells by a novel hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel. Int J Oncol. 2008 Jul;33(1):103-11.
- FPA 124
Catalog No.:BCC7518
CAS No.:902779-59-3
- UBP 310
Catalog No.:BCC6052
CAS No.:902464-46-4
- NVP-LCQ195
Catalog No.:BCC1816
CAS No.:902156-99-4
- AT7519 Hydrochloride
Catalog No.:BCC1376
CAS No.:902135-91-5
- Gossypolone
Catalog No.:BCC1375
CAS No.:4547-72-2
- GSK 5959
Catalog No.:BCC5597
CAS No.:901245-65-6
- Fostamatinib (R788)
Catalog No.:BCC5082
CAS No.:901119-35-5
- TAME
Catalog No.:BCC4367
CAS No.:901-47-3
- Rebamipide
Catalog No.:BCC4836
CAS No.:90098-04-7
- AVX 13616
Catalog No.:BCC5407
CAS No.:900814-48-4
- Chondroitin sulfate
Catalog No.:BCN1312
CAS No.:9007-28-7
- 5-O-beta-D-Glucopyranosylmyricanol
Catalog No.:BCN8044
CAS No.:90052-02-1
- 7-Xylosyl-10-deacetyltaxol B
Catalog No.:BCN7667
CAS No.:90332-64-2
- 7-Xylosyl-10-deacetyltaxol C
Catalog No.:BCN7663
CAS No.:90332-65-3
- 7-Xylosyltaxol
Catalog No.:BCN5341
CAS No.:90332-66-4
- Shizukolidol
Catalog No.:BCN4444
CAS No.:90332-92-6
- Seneciphyllinine
Catalog No.:BCN2132
CAS No.:90341-45-0
- 10-O-Coumaroyl-10-O-deacetylasperuloside
Catalog No.:BCN7614
CAS No.:903519-82-4
- 7-Xylosyltaxol B
Catalog No.:BCN7675
CAS No.:90352-19-5
- Bicalutamide
Catalog No.:BCC2481
CAS No.:90357-06-5
- Pitolisant hydrochloride
Catalog No.:BCC1863
CAS No.:903576-44-3
- Ligularinine
Catalog No.:BCN2117
CAS No.:90364-90-2
- Neoligularidine
Catalog No.:BCN2137
CAS No.:90364-91-3
- Ligularizine
Catalog No.:BCN2091
CAS No.:90364-92-4
Transport of a hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel, by human intestinal epithelial Caco-2 cells.[Pubmed:20414861]
Planta Med. 2010 Oct;76(14):1592-5.
7-Xylosyl-10-deacetylpaclitaxel is an active compound used in traditional Chinese medicine to treat cancer. However, pharmacokinetic studies yielded low plasma concentrations of 7-xylosyl-10-deacetylpaclitaxel after its oral administration in preclinical trials. Therefore, we investigated whether the observed low oral bioavailability of this compound is due to poor absorption. We studied the transepithelial flux of 7-xylosyl-10-deacetylpaclitaxel using the human colonic cell line Caco-2 as a model and found out that its flux (at a concentration range of 0.5-20 microM) across the Caco-2 cell layer was linear with time for up to 3 hr. The apparent maximal concentration (K (M)) of the active efflux component was 93.4 microM. Verapamil (50 microM) and tetrandrine (25 microM) significantly decreased the active transport component. These data support the conclusion that rapid passive diffusion of 7-xylosyl-10-deacetylpaclitaxel through the intestinal epithelium is partially counteracted by the action of an outwardly directed efflux pump, presumably P-glycoprotein. The relatively high apparent permeability coefficient ( P(app)) for the apical to basolateral 7-xylosyl-10-deacetylpaclitaxel transport (16.3 +/- 6.3 x 10 (-6) cm/s; n = 3) suggests that the drug may still be effectively absorbed in the intestinal tract.